U.S. Markets closed

Initiating Free Research Reports on Intuitive Surgical and Three Other Medical Supplies Equities

Stock Research Monitor: ILMN, MMSI, and NXTM

LONDON, UK / ACCESSWIRE / July 24, 2018/ If you want a free Stock Review on ISRG sign up now at www.wallstequities.com/registration. WallStEquities.com scans Illumina Inc. (NASDAQ: ILMN), Intuitive Surgical Inc. (NASDAQ: ISRG), Merit Medical Systems Inc. (NASDAQ: MMSI), and Nxstage Medical Inc. (NASDAQ: NXTM). Companies in the Medical Instruments and Supplies manufacturing industry primarily research, develop, and produce nonelectronic medical, surgical, dental and veterinary instruments and apparatus, such as syringes, anesthesia apparatus, blood transfusion equipment, catheters, surgical clamps, and medical thermometers.All you have to do is sign up today for this free limited time offer by clicking the link below.



San Diego, California headquartered Illumina Inc.'s stock finished Monday's session 0.04% lower at $311.04 with a total trading volume of 693,635 shares. The Company's shares have advanced 8.74% in the past month, 26.52% over the previous three months, and 80.05% over the past year. The stock is trading above its 50-day and 200-day moving averages by 10.21% and 29.12%, respectively. Furthermore, shares of Illumina, which provides sequencing and array-based solutions for genetic analysis, have a Relative Strength Index (RSI) of 73.17.

On July 10th, 2018, Illumina announced that it will issue its results for Q2 2018 following the close of market on July 30th, 2018. On the same day at 5:00 p.m. ET, Francis deSouza, President and CEO, and Sam Samad, Senior Vice President and CFO, will host a conference call to discuss the Company's results. Get the full research report on ILMN for free by clicking below at:


Intuitive Surgical

Shares in Sunnyvale, California headquartered Intuitive Surgical Inc. ended at $519.87, up slightly by 0.60% from the last trading session. The stock recorded a trading volume of 951,834 shares, which was above its three months average volume of 810,900 shares. The Company's shares have gained 6.73% in the last month, 16.08% in the previous three months, and 68.16% over the past year. The stock is trading 7.28% above its 50-day moving average and 22.50% above its 200-day moving average. Moreover, shares of Intuitive Surgical, which designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories, have an RSI of 64.25.

On July 05th, 2018, Intuitive Surgical announced that theUS FDA granted clearance for the Company's fully wristed, 60mm stapler. SureForm 60™, a single-patient use 60mm stapler, offers 120 degrees of fully wristed articulation, which is an industry first.

On July 20th, 2018, research firm Goldman reiterated its ‘Buy' rating on the Company's stock with an increase of the target price from $540 a share to $630 a share. Gain free access to the research report on ISRG at:


Merit Medical Systems

South Jordan, Utah headquartered Merit Medical Systems Inc.'s stock ended yesterday's session 0.72% higher at $56.20. A total volume of 451,852 shares was traded, which was above their three months average volume of 426,770 shares. The Company's shares have advanced 12.51% in the past month, 22.71% over the previous three months, and 46.93% over the past year. The stock is trading 6.81% and 21.40% above its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which designs, develops, manufactures, and markets various disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy, have an RSI of 61.25. Signing up today on Wall St. Equities will give you access to the latest report on MMSI at:


Nxstage Medical

On Monday, shares in Lawrence, Massachusetts headquartered Nxstage Medical Inc. recorded a trading volume of 170,763 shares. The stock finished 0.14% lower at $27.60. The Company's shares have advanced 7.27% in the previous three months and 15.34% over the past year. The stock is trading above its 200-day moving average by 6.25%. Furthermore, shares of Nxstage Medical, which develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure, have an RSI of 45.06. Register now for today's free coverage on NXTM at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities